lifestyle.californiaconsumerbanking.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Cognition Therapeutics, Inc.
Cognition Therapeutics Receives Second Philanthropic Donation to Extend Ongoing Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
May 14, 2026
Cognition Therapeutics Reports Financial Results for the First Quarter 2026 and Provides Business Update
May 9, 2026
Cognition Therapeutics to Present at Needham Virtual Healthcare Conference
May 5, 2026
Cognition Therapeutics CEO Issues Letter to Shareholders
May 4, 2026
Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update
May 4, 2026
Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results
May 3, 2026
Cognition Therapeutics Presents Evidence of Zervimesine’s Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026
May 2, 2026
Cognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis
April 29, 2026
Cognition Therapeutics Extends Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
March 9, 2026
Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies
January 27, 2026